Showing results (21-30 of 32) with videos related to
Sort By:
Pageof 4
Current Oncology (Toronto, Ont.)|August 27, 2025
Focused Ultrasound for Sarcomas: A Narrative ReviewNidhi Kuchimanchi, Nicolle Sul, Sai Gajula, et al.Cancers|February 13, 2026
Multi-Targeted TKIs in Patients with Advanced Ewing Sarcoma: A Systematic Review and Single-Arm Meta-AnalysisIsabella Michelon, Caio Ernesto do Rêgo Castro, Ana Paula Querino Belluco, et al.Cancers|July 27, 2024
Neurocognitive Adverse Events Related to Lorlatinib in Non-Small Cell Lung Cancer: A Systematic Review and Meta-AnalysisJonathan N Priantti, Maysa Vilbert, Francisco Cezar Aquino de Moraes, et al.Journal for Immunotherapy of Cancer|August 14, 2024
Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1/CTLA-4 checkpoint inhibitor, in combination with pembrolizumabLudimila Cavalcante, Sreenivasa Chandana, Nehal Lakhani, et al.Neuro-Oncology Advances|April 11, 2022
Malignant glioma subset from actuate 1801: Phase I/II study of 9-ING-41, GSK-3β inhibitor, monotherapy or combined with chemotherapy for refractory malignanciesYazmin Odia, Ludimila Cavalcante, Howard Safran, et al.Cancer Biology & Therapy|July 11, 2022
Clinical activity of 9-ING-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in refractory adult T-Cell leukemia/lymphomaAndrew Hsu, Kelsey E Huntington, Andre De Souza, et al.JCO Precision Oncology|September 7, 2023
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial CancersLudimila Cavalcante, Sachin Kumar Deshmukh, Jennifer R Ribeiro, et al.JCO Precision Oncology|November 22, 2024
Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-AnalysisJonathan N Priantti, Yu Fujiwara, Francisco Cezar Aquino de Moraes, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|April 14, 2024
Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. population-based studyAbdul Qahar Khan Yasinzai, Bisma Tareen, Katharine Tracy, et al.Journal for Immunotherapy of Cancer|August 3, 2024
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, et al.Pageof 4